Allison Wills is a Partner and Consultant at 20Sense Specialty Pharmaceutical Consulting. 20Sense supports Canada’s specialty pharmaceutical stakeholders to optimize data, insights and programs that deliver better outcomes for patients and value for payers.
As publisher of the The 20Sense Report, she is dedicated to sharing market insights that push innovation and create value for the Canadian specialty pharmaceutical industry at-large.
Allison previously worked at Janssen specializing in trade relations, hospital contracting, access and patient support program management for specialty pharmaceutical products.
Day 1: Oct 6, 2020
Day 2: Oct 7, 2020
What’s Next for Patient Support Programs?
Patient support programs to allow patients access to specialty medications have now become a mainstay in the marketplace over the past couple of decades. However, there are shifting market dynamics that will likely require your company to develop a new approach to these critical programs. Gain insight that will allow your company to take incisive steps in forward planning by:
- Understanding what tensions are now surfacing between support services required and financial sustainability
- Determining to what extent the entry of biosimilar PSPs increase competition
- Hearing what vision may be emerging in how PSPs could be re-designed
Gain an edge in patient retention with an improved PSP